The role of microbiota in cancer therapy

Current Opinion in Immunology

Volumn 39, Issue , 2016, Pages 75-81

  Perez Chanona, Ernesto ^a,b   Trinchieri, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DNA; INTERLEUKIN 10 ANTIBODY; MONOCLONAL ANTIBODY; OXALIPLATIN; REACTIVE OXYGEN METABOLITE;

BACTERIAL TRANSLOCATION; BONE MARROW CELL; CANCER THERAPY; COMMENSALISM; CYTOKINE RELEASE; DNA DAMAGE; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE FLORA; MICROBIAL COMMUNITY; NEOPLASM; NONHUMAN; REGULATORY MECHANISM; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; MICROBIOLOGY; NEOPLASMS; SYMBIOSIS;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; NEOPLASMS; SYMBIOSIS;

EID: 84955295491     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.01.003     Document Type: Review

References (32)

1. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
2. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994, 61:1-241.
3. Plottel C.S., Blaser M.J. Microbiome and malignancy. Cell Host Microbe 2011, 10:324-335.
4. Sommer F., Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
5. Hollister E.B., Gao C., Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014, 146:1449-1458.
6. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
7. Schwabe R.F., Jobin C. The microbiome and cancer. Nat Rev Cancer 2013, 13:800-812.
8. Sears C.L., Garrett W.S. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014, 15:317-328.
9. Lakritz J.R., Poutahidis T., Mirabal S., Varian B.J., Levkovich T., Ibrahim Y.M., Ward J.M., Teng E.C., Fisher B., Parry N., et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget 2015, 6:9387-9396.
10. Rutkowski M.R., Stephen T.L., Svoronos N., Allegrezza M.J., Tesone A.J., Perales-Puchalt A., Brencicova E., Escovar-Fadul X., Nguyen J.M., Cadungog M.G., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015, 27:27-40.
11. Paulos C.M., Wrzesinski C., Kaiser A., Hinrichs C.S., Chieppa M., Cassard L., Palmer D.C., Boni A., Muranski P., Yu Z., et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007, 117:2197-2204.
12. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
13. Madondo M.T., Quinn M., Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev 2016, 42:3-9.
14. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
15. Yang Y., Torchinsky M.B., Gobert M., Xiong H., Xu M., Linehan J.L., Alonzo F., Ng C., Chen A., Lin X., et al. Focused specificity of intestinal T17 cells towards commensal bacterial antigens. Nature 2014.
16. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillere R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
17. Scheiermann J., Klinman D.M. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 2014, 32:6377-6389.
18. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M.P., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196:541-549.
19. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005, 65:3437-3446.
20. Iida N., Dzutsev A., Stewart C.A., Smith L., Bouladoux N., Weingarten R.A., Molina D.A., Salcedo R., Back T., Cramer S., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970.
21. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
22. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
23. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
24. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372:2006-2017.
25. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
26. Teply B.A., Lipson E.J. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 2014, 28(Suppl 3):30-38.
27. Vetizou M., Pitt J.M., Daillere R., Lepage P., Waldschmitt N., Flament C., Rusakiewicz S., Routy B., Roberti M.P., Duong C.P., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015, 350:1079-1084.
28. Sivan A., Corrales L., Hubert N., Williams J.B., Aquino-Michaels K., Earley Z.M., Benyamin F.W., Lei Y.M., Jabri B., Alegre M.L., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089.
29. Dzutsev A., Goldszmid R.S., Viaud S., Zitvogel L., Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015, 45:17-31.
30. Xuan C., Shamonki J.M., Chung A., Dinome M.L., Chung M., Sieling P.A., Lee D.J. Microbial dysbiosis is associated with human breast cancer. PLoS ONE 2014, 9:e83744.
31. Goldszmid R.S., Dzutsev A., Viaud S., Zitvogel L., Restifo N.P., Trinchieri G. Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunol Res 2015, 3:103-109.
32. Ganal S.C., Sanos S.L., Kallfass C., Oberle K., Johner C., Kirschning C., Lienenklaus S., Weiss S., Staeheli P., Aichele P., et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012, 37:171-186.